Dr. Tarek Alhamad, MD

Dr. Alhamad practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Alhamad's NPI, 1659533529, was assigned on July 1, 2008. Dr. Alhamad holds Missouri license 2014011744.

Dr. Alhamad's primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Alhamad also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Alhamad's primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Alhamad is also affiliated with Missouri Baptist Medical Center. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Alhamad to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Alhamad practices, 6 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Alhamad's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Alhamad is licensed in Missouri.

CMS data shows 566 Medicare services from Dr. Alhamad across 7 procedure codes in 2024, for 255 Medicare patients. Medicare paid $42,046 for them.

CMS counts 255 Medicare patients who saw Dr. Alhamad in 2024. The largest group is under 65, with 125 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 29% are also on Medicaid. Their average risk score is 4.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Alhamad's median patient age at 65, with 41% women.

In 2024, Dr. Alhamad wrote 7,771 Medicare Part D claims for 818 patients. 97% of them were for generic drugs. CMS names the drug for 7,464 of them, across 60 drugs with 11 or more claims each, at $210,673 in total drug cost. In 2023, CMS named 7,444 claims across 67 drugs.

Dr. Alhamad accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Alhamad as offering telehealth.

Dmand AI links 87 papers to Dr. Alhamad, published from 2011 to 2025. 2021 was the busiest year, with 13. The most frequent topics are Kidney Transplantation, Graft Survival and Graft Rejection. Dr. Alhamad has published most often in Am J Transplant. Dr. Alhamad's most frequent co-authors are Krista L. Lentine, MD, PhD, Ronald Fairbairn Parsons, MD and Haris Farooq Murad, MD.

Dmand AI links Dr. Alhamad to 1 clinical trial.

CMS Open Payments shows 316 general payments to Dr. Alhamad from 23 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 52% of the total. Veloxis Pharmaceuticals, Inc. paid the most, $147,880. It also lists 2 research payments totaling $15,413 in 2021.